3-iodo-1-methyl-4-nitro-1H-pyrazole | 186298-52-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-iodo-1-methyl-4-nitro-1H-pyrazole
• 英文别名: 3-iodo-1-methyl-4-nitropyrazole
• CAS: 186298-52-2
• 化学式: C₄H₄IN₃O₂
• 分子量: 252.999
• InChiKey: QVKHKGMSULLBTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-iodo-1-methyl-4-nitro-1H-pyrazole 在 硝酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以64%的产率得到1-methyl-3,4-dinitropyrazole
  参考文献：
  名称：

  Faujasite catalyzed nitrodeiodination of iodopyrazoles

  摘要：

  Nitrodeiodination of iodopyrazoles using nitric acid/Faujasite has been investigated. The present procedure is simple, rapid and convenient and requires no sulfuric acid or oleum and may be applied for the synthesis of several nitropyrazoles in good yields in drug and pharmaceutical industries. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.catcom.2013.07.032
• 作为产物：
  描述：

  1-methyl-4-nitro-1H-pyrazol-3-ylamine 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 1.33h， 生成 3-iodo-1-methyl-4-nitro-1H-pyrazole
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  [FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DES KINASES, ET INDICATIONS ASSOCIÉES

  摘要：

  公开号：

  WO2017019804A3

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150133451A1

  公开（公告）日：2015-05-14

  The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有IRAK-4抑制作用的杂环化合物，该化合物对于预防或治疗炎症性疾病、自身免疫疾病、骨关节退行性疾病、肿瘤性疾病等具有用处，并且包含该化合物的药物。本发明涉及一种由下式（I）表示的化合物： 其中每个符号如规范中定义的那样，或其盐。
• 一种化合物及其制备方法和医药上的应用
  申请人：南京谷睿生物科技有限公司

  公开号：CN110734456A

  公开（公告）日：2020-01-31

  本发明提供了一种化合物及及其制备方法和医药上的应用，所述化合物具有通式(I)所示的结构，还可为所述化合物的互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其可药用盐。本发明提供的具有通式(I)结构的化合物通过选择特定的主链结构以及其相应的取代基，使得得到的化合物能够作为精氨酸酶抑制剂，且活性较高，在多种疾病中具有潜在的治疗前景。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US09321757B2

  公开（公告）日：2016-04-26

  The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有IRAK-4抑制作用的杂环化合物，该化合物可用于预防或治疗炎症性疾病、自身免疫性疾病、骨关节退行性疾病、肿瘤性疾病等，以及包含该化合物的药物。本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中所定义，或其盐。
• Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling
  作者：Mark Zak、Emily J. Hanan、Patrick Lupardus、David G. Brown、Colin Robinson、Michael Siu、Joseph P. Lyssikatos、F. Anthony Romero、Guiling Zhao、Terry Kellar、Rohan Mendonca、Nicholas C. Ray、Simon C. Goodacre、Peter H. Crackett、Neville McLean、Christopher A. Hurley、Po-wai Yuen、Yun-Xing Cheng、Xiongcai Liu、Marya Liimatta、Pawan Bir Kohli、Jim Nonomiya、Gary Salmon、Gerry Buckley、Julia Lloyd、Paul Gibbons、Nico Ghilardi、Jane R. Kenny、Adam Johnson

  DOI：10.1016/j.bmcl.2019.04.008

  日期：2019.6

  Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
• Silica–Sulfuric Acid Catalyzed Nitrodeiodination of Iodopyrazoles
  作者：P. Ravi、Girish M. Gore、Arun K. Sikder、Surya P. Tewari

  DOI：10.1080/00397911.2011.584261

  日期：2012.12.1

  We report here the synthesis of nitropyrazoles in good to excellent yields from iodopyrazoles over silica-sulfuric acid catalyst for the first time. The present procedure require less acid, offers a simplified workup procedure, and may be applied for the nitration of a wide variety of iodoazoles in drug and pharmaceutical industries.